Nature Communications (Mar 2018)
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
- Valeriy Domenyuk,
- Zoran Gatalica,
- Radhika Santhanam,
- Xixi Wei,
- Adam Stark,
- Patrick Kennedy,
- Brandon Toussaint,
- Symon Levenberg,
- Jie Wang,
- Nianqing Xiao,
- Richard Greil,
- Gabriel Rinnerthaler,
- Simon P. Gampenrieder,
- Amy B. Heimberger,
- Donald A. Berry,
- Anna Barker,
- John Quackenbush,
- John L. Marshall,
- George Poste,
- Jeffrey L. Vacirca,
- Gregory A. Vidal,
- Lee S. Schwartzberg,
- David D. Halbert,
- Andreas Voss,
- Daniel Magee,
- Mark R. Miglarese,
- Michael Famulok,
- Günter Mayer,
- David Spetzler
Affiliations
- Valeriy Domenyuk
- Caris Life Sciences
- Zoran Gatalica
- Caris Life Sciences
- Radhika Santhanam
- Caris Life Sciences
- Xixi Wei
- Caris Life Sciences
- Adam Stark
- Caris Life Sciences
- Patrick Kennedy
- Caris Life Sciences
- Brandon Toussaint
- Caris Life Sciences
- Symon Levenberg
- Caris Life Sciences
- Jie Wang
- Caris Life Sciences
- Nianqing Xiao
- Caris Life Sciences
- Richard Greil
- IIIrd Medical Department, Oncologic Center, Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg
- Gabriel Rinnerthaler
- IIIrd Medical Department, Oncologic Center, Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg
- Simon P. Gampenrieder
- IIIrd Medical Department, Oncologic Center, Paracelsus Medical University Salzburg, Austria and Salzburg Cancer Research Institute, and Cancer Cluster Salzburg
- Amy B. Heimberger
- Department of Neurosurgery, University of Texas MD Anderson Cancer Center
- Donald A. Berry
- Berry Consultants
- Anna Barker
- Complex Adaptive Systems Initiative, Arizona State University
- John Quackenbush
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute
- John L. Marshall
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
- George Poste
- Caris Life Sciences
- Jeffrey L. Vacirca
- North Shore Hematology Oncology Associates Cancer Center
- Gregory A. Vidal
- Division of Hematology and Oncology, University of Tennessee Health Science Center
- Lee S. Schwartzberg
- Division of Hematology and Oncology, University of Tennessee Health Science Center
- David D. Halbert
- Caris Life Sciences
- Andreas Voss
- Caris Life Sciences
- Daniel Magee
- Caris Life Sciences
- Mark R. Miglarese
- Caris Life Sciences
- Michael Famulok
- Caris Life Sciences
- Günter Mayer
- Caris Life Sciences
- David Spetzler
- Caris Life Sciences
- DOI
- https://doi.org/10.1038/s41467-018-03631-z
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 9
Abstract
Patients’ selection is particularly important in cancer treatment. Here the authors present a proof-of-principle methodology that could be potentially important in assisting therapeutic decisions in the treatment of breast cancer patients.
